SCHEMBL3129975

SCHEMBL3129975

Cc1noc(C)c1C(=O)N1CCCC(c2nc(Oc3cccc(F)c3)no2)C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ RAB9A P51151 2/20 0.53
▸ ALDH1A1 P00352 2/20 0.51
▸ LMNA P02545 2/20 0.51
▸ TSHR P16473 2/20 0.51
▸ HTT P42858 2/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ TP53 P04637 1/20 0.51
▸ ALOX15 P16050 1/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.51
▸ POLB P06746 1/20 0.50
▸ ATM Q13315 1/20 0.49
▸ GFER P55789 1/20 0.47
▸ GRM5 P41594 1/20 0.47
▸ BTK Q06187 1/20 0.47
▸ HSD11B1 P28845 1/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3129959 1.00 L3MBTL1 (0.55) L3MBTL1RAB9AALDH1A1LMNATSHR
SCHEMBL4644183 0.86 RAB9A (0.67) L3MBTL1RAB9AALDH1A1LMNATSHR
SCHEMBL4644196 0.86 RAB9A (0.67) L3MBTL1RAB9AALDH1A1LMNATSHR
SCHEMBL3137416 0.86 L3MBTL1 (0.69) L3MBTL1RAB9AALDH1A1POLBGRM5
SCHEMBL3137399 0.86 L3MBTL1 (0.69) L3MBTL1RAB9AALDH1A1POLBGRM5
SCHEMBL3137836 0.86 L3MBTL1 (0.54) L3MBTL1RAB9AALDH1A1LMNATSHR
SCHEMBL3137821 0.86 L3MBTL1 (0.54) L3MBTL1RAB9AALDH1A1LMNATSHR
SCHEMBL3142302 0.85 HSD11B1 (0.61) L3MBTL1RAB9AALDH1A1LMNATSHR
SCHEMBL3142320 0.85 HSD11B1 (0.61) L3MBTL1RAB9AALDH1A1LMNATSHR
SCHEMBL3140639 0.85 GRM5 (0.63) L3MBTL1RAB9ATSHRPOLBATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004284-A1 Novel Heterocyclic Compounds as Positive Allosteric Modulators of Metabotropic Glutamate Receptors ADDEX PHARMA SA (CH) 2010-01-07 — — US claimed
US-20100004284-A1 Novel Heterocyclic Compounds as Positive Allosteric Modulators of Metabotropic Glutamate Receptors ADDEX PHARMA SA (CH) 2010-01-07 — — US disclosed
EP-1896464-A1 NOVEL HETEROCYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS Addex Pharma SA (CH) 2008-03-12 — — EP disclosed
WO-2006129199-A1 NOVEL HETEROCYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2006-12-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004284-A1 Novel Heterocyclic Compounds as Positive Allosteric Modulators of Metabotropic Glutamate Receptors GRM5, GRM1, GRIK5 L3MBTL1 3297/4885RAB9A 1083/4885ALDH1A1 4618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback